Baseline characteristics of patients undergoing transcatheter pulmonary vein isolation
| Total group N=414 | BMI<30 N=303 | BMI≥30 N=111 | P values | |
| Age, mean±SD (years) | 56±10 | 56±10 | 56±10 | 0.859 |
| Males, n (%) | 316 (76%) | 236 (78%) | 80 (73%) | 0.298 |
| Chronic heart failure, n (%) | 24 (6%) | 13 (4%) | 11 (10%) | 0.034 |
| Diabetes mellitus, n (%) | 21 (5%) | 12 (4%) | 9 (8%) | 0.124 |
| Previous stroke, n (%) | 17 (4%) | 11 (4%) | 6 (5%) | 0.407 |
| Hypertension, n (%) | 213 (51%) | 141 (46%) | 72 (65%) | 0.001 |
| Vascular disease, n (%) | 47 (11%) | 36 (12%) | 11 (10%) | 0.726 |
| CHADS2VA2Sc score>1, n (%) | 142 (34%) | 94 (31%) | 48 (43%) | 0.019 |
| Hypercholesterolaemia, n (%) | 79 (19%) | 59 (19%) | 20 (18%) | 0.888 |
| Thyroid dysfunction, n (%) | 35 (9%) | 21 (7%) | 14 (13%) | 0.072 |
| Self-reported OSAS, n (%) | 13 (4%) | 5 (2%) | 8 (7%) | 0.013 |
| Time since first AF episode, median (IQR) (months) | 63 (29–118) | 66 (30–121) | 48 (23–108) | 0.073 |
| Paroxysmal AF, n (%) | 311 (75%) | 235 (77%) | 76 (68%) | 0.095 |
| Non-paroxysmal AF, n (%) | 103 (25%) | 69 (23%) | 34 (32%) | 0.095 |
| LA diameter parasternal, mm (mean±SD) | 42±6 | 41±7 | 44±5 | <0.001 |
| LVEF, mean±SD | 57±6 | 58±5 | 57±7 | 0.234 |
| AAD use | ||||
| Class I or III, n (%) | 275 (72%) | 200 (66%) | 75 (68%) | 0.921 |
| Amiodarone, n (%) | 93 (24%) | 58 (19%) | 35 (32%) | 0.010 |
AAD, antiarrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; LVEF, LA left atrial, left ventricular ejection fraction; OSAS, obstructive sleep apnoea syndrome.